EANS-Adhoc: LifeWatch announces joint development of new breakthrough test for its wireless cardiac monitoring platform (with document)

--------------------------------------------------------------------------------
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
distribution. The issuer is solely responsible for the content of this
announcement.
--------------------------------------------------------------------------------

24.02.2012

The testing technology will be deployed on LifeWatch wireless cardiac monitors
in coming months.

Neuhausen am Rheinfall/Switzerland - LifeWatch AG (SIX Swiss Exchange:LIFE), the
leading wireless cardiac monitoring service provider in the U.S., announced
today the joint development of additional Sympathetic and Parasympathetic
testing with the ANSAR Group.

For the first time in the wireless cardiac monitoring industry, the treating
physician will be able to measure individual parasympathetic and sympathetic
responses of their patient. This information will be significant in providing
additional clinical data for patients with Atrial Fibrillation, Syncope
(fainting), Congestive Heart Failure, Cardiac Autonomic Neuropathy (associated
with increased risk of mortality and morbidity) and Hypertension. These
conditions together affect an estimated 99 million Americans1. An additional
subset of patients who could benefit from this test includes millions of
Americans who are currently prescribed Beta blockers.

"The Ansar test integrated with our ACT cardiac telemetry platform is a very
important technological advance", stated Dr. Yacov Geva, Chairman and CEO of
LifeWatch AG. "For the first time ever, a physician will be provided with
invaluable clinical information about a patient's sympathetic and
parasympathetic nervous system in a comprehensive arrhythmia report via an
outpatient cardiac monitoring platform. The data generated from the Ansar test
and LifeStar ACT cardiac monitor will assist in guiding therapy. Physicians will
be able to diagnose vasovagal or neurocardiogenic syncope, orthostasis,
arrhythmia or palpitations caused by surges in the parasympathetic or
sympathetic tone with the LifeWatch ACT monitor. This has the potential to
improve patient outcomes, reduce medication loads, hospitalizations, unnecessary
deaths and overall healthcare costs. It is an honor for LifeWatch to be able to
empower physicians with this capability."

The Ansar parasympathetic and sympathetic response monitoring test allows for
the differential diagnosis of three main causes of syncope (neurogenic,
vasovagal and cardiogenic), and other causes of dizziness (including orthostasis
and arrhythmia). These individual measurements can be recorded preceding an
arrhythmic event, which will provide physicians with clear and precise
documentation of the causes of underlying syncope, dizziness, arrhythmia, chest
pain, or sleep disordered cardiac disturbances, etc., and aid the physician in
the differential diagnosis and guiding therapy.

The easy-to-use test utilizes a LifeStar ACT wireless cardiac monitor enabling
real-time viewing of the ECG before the patient is sent home for continued
arrhythmia monitoring. The Ansar test, which is reimbursable, includes
physiological parameters equivalent to a head-up tilt table test, and has
demonstrated higher rates of specificity and sensitivity2. This test is
encouraged by many of the leading professional medical societies in the United
States, including the AHA, ADA, JDFI, AAN, AAFP, NIH. Published, peer-reviewed,
parasympathetic and sympathetic response testing data shows how to optimize
therapy for many difficult to treat conditions, including Atrial Fibrillation,
Heart Failure, Hypertension, Dizziness (including syncope) and sleep disorders.
This technology will be available in the US in the following months.

Sources: 1. Circulation 2012, 125:e2-e220, 2. Am Heart J 1997;134:316-20.

About LifeWatch AG:

LifeWatch AG, headquartered in Neuhausen am Rheinfall and listed on SIX Swiss
Exchange (LIFE), Switzerland, is the leading healthcare technology and solution
company, specializing in advanced telehealth systems and wireless remote patient
monitoring services. LifeWatch services cater to individuals, ranging from
high-risk and chronically ill patients, to consumers of health and wellness
products. LifeWatch has subsidiaries in the United States, the Netherlands,
Japan, the United Kingdom, Switzerland and Israel. LifeWatch AG is the parent
company of LifeWatch Services Inc., a leading US-based cardiac monitoring
service provider, and manufacturer of telecardiology products. LifeWatch is also
introducing a new program for Home Sleep Testing of Obstructive Sleep Apnea
(OSA) patients under the brand name NiteWatch. For additional information,
please visit http://www.lifewatch.com.

Sign-up for customized E-mail alerts and documentation requests is available at
http://production.investis.com/lifewatch/alert-service/

This press release includes forward-looking statements. All statements other
than statements of historical facts contained in this press release, including
statements regarding future results of operations and financial position,
business strategy and plans and objectives for future operations, are
forward-looking statements. The words "believe," "may," "will," "estimate,"
"continue," "anticipate," "intend," "expect" and similar expressions are
intended to identify forward-looking statements. LifeWatch AG has based these
forward-looking statements largely on current expectations and projections about
future events and financial trends that it believes may affect the financial
condition, results of operations, business strategy, short term and long term
business operations and objectives, and financial needs. These forward-looking
statements are subject to a number of risks, uncertainties and assumptions. In
light of these risks, uncertainties and assumptions, the forward-looking events
and circumstances described may not occur and actual results could differ
materially and adversely from those anticipated or implied in the
forward-looking statements. All forward-looking statements are based only on
data available to LifeWatch AG at the time of the issue of this press release.
LifeWatch AG does not undertake any obligation to update any forward-looking
statements contained in this press release as a result of new information,
future events or otherwise.

THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF AMERICA AND
SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR PUBLICATIONS WITH A
GENERAL CIRCULATION IN THE UNITED STATES. THIS PRESS RELEASE DOES NOT CONSTITUTE
AN OFFER OF SECURITIES OF LIFEWATCH AG OR ANY OF ITS SUBSIDIARIES FOR SALE IN
THE UNITED STATES OR AN INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES
OF LIFEWATCH AG OR ITS SUBSIDIARIES IN THE UNITED STATES. IN ADDITION, THE
SECURITIES OF LIFEWATCH AG AND ITS SUBSIDIARIES HAVE NOT BEEN REGISTERED UNDER
THE UNITED STATES SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR DELIVERED
WITHIN THE UNITED STATES OR TO U.S. PERSONS ABSENT REGISTRATION UNDER OR AN
APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE UNITED STATES
SECURITIES LAWS. ANY PUBLIC OFFERING OF SECURITIES TO BE MADE IN THE UNITED
STATES WILL BE MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM LIFEWATCH
AG OR ITS SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED INFORMATION
ABOUT THE ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL STATEMENTS OF THE
ISSUER.

Further inquiry note:
Sensus Investor and Public Relations GmbH, Zürich:
Tel+41 433665511 | Fax+41 43 366 55 12|Email lifewatch@sensus.ch
end of announcement euro adhoc
--------------------------------------------------------------------------------

Attachments with Announcement:
----------------------------------------------
http://resources.euroadhoc.com/us/9HSfZYNF

issuer: LifeWatch AG
Rundbuckstrasse 6
CH-8212 Neuhausen am Rheinfall
phone: +41 52 632 00 50
FAX: +41 52 632 00 51
mail: users@lifewatch.com
WWW: www.lifewatch.com
sector: Healthcare Providers
ISIN: CH0012815459
indexes: SPI, SPIEX
stockmarkets: free trade: Berlin, Open Market / XETRA: Frankfurt, Main Standard:
SIX Swiss Exchange
language: English

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | EAE

print